Bempedoic acid in the updated recommendations for the management of dyslipidemias ESC/EAS 2025

Czech version

Authors: Ľubomíra Fábryová ^1,2,3,4
Authors‘ workplace: Ústav výživy, Fakulta ošetrovateľstva a zdravotníckych odborných štúdií, Slovenská zdravotnícka univerzita v Bratislave ¹; MetabolKLINIK s. r. o., Ambulancia pre diabetológiu, poruchy látkovej premeny a výživy, MED PED centrum, Bratislava ²; Biomedicínske centrum Slovenskej Akadémie Vied., Bratislava ³; Inštitút prevencie a intervencie, Vysoká škola zdravotníctva a sociálnej práce sv. Alžbety, Bratislava ⁴
Published in: AtheroRev 2026; 11(1): 10-14
Category: Guidelines

Overview

The 2025 ESC/EAS update on the management of dyslipidemias highlights the need for more intensive and individualized lipid-lowering therapy in patients at high and very high cardiovascular risk. In this context, bempedoic acid has been incorporated as an oral non-statin therapy with demonstrated clinical benefit. Results from the CLEAR Outcomes trial confirmed a reduction in major cardiovascular events in patients with statin intolerance. ESC/EAS recommendations support its use in both primary and secondary prevention for patients who do not achieve LDL-cholesterol targets despite standard therapy. Bempedoic acid represents an appropriate step in treatment escalation between ezetimibe and biologic therapy. From a pharmacoeconomic perspective, it offers a favorable cost-effectiveness profile compared with parenteral lipid-lowering agents. Its oral formulation and good tolerability may improve treatment adherence. Higher adherence translates into better LDL-C target achievement and more effective prevention of cardiovascular events. Targeted use of bempedoic acid may delay the need for costly biologic therapies, thereby optimizing healthcare resource allocation. Bempedoic acid thus represents a rational component of contemporary dyslipidemias management strategies.

Sources

Mach F, Koskinas KC, Roeters van Lennep JE et al. [ESC/EAS Scientific Document Group]. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2025; 46(42): 4359 –⁠ 4378. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehaf190>.Erratum in: Eur Heart J 2025:ehaf1036. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehaf1036>.
Mach F, Baigent C, Catapano AL et al. [ESC Scientific Document Group]. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111–188. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz455>. Erratum in: Eur Heart J 2020; 41(44): 4255. Dostupné z DOI: <http://dx.doi. org/10.1093/eurheartj/ehz826>.
Nissen SE, Lincoff AM, Brennan D et al. [CLEAR Outcomes Investigators]. Bempedoic Acid and Cardiovascular Outcomes in StatinIntolerant Patients. N Engl J Med 2023; 388(15): 1353–1364. Dostupné z DOI: <http:// dx.doi.org/10.1056/NEJMoa2215024>.
McGuigan A, Blair HA. Bempedoic Acid: A Review in Cardiovascular Risk Reduction in StatinIntolerant Patients. Am J Cardiovasc Drugs 2025; 25(1): 7–16. Dostupné z DOI: <http://dx.doi.org/10.1007/s40256–024 –⁠ 00714–9>.
Bays HE, Bloedon L, Brennan D et al. Bempedoic Acid for Prevention of Cardiovascular Events in People With Obesity: A CLEAR Outcomes Subset Analysis. J Am Heart Assoc 2025; 14(4): e037898. Dostupné z DOI: <http:// dx.doi.org/10.1161/JAHA.124.037898>.
Pinkosky SL, Newton RS, Day EA et al. Liver specific ATPcitrate lyase inhibition by bempedoic acid decreases LDLC and attenuates atherosclerosis. Nat Commun 2016; 28(7): 13457. Dostupné z DOI: <http://dx.doi. org/10.1038/ncomms13457>.
Ballantyne CM, Laufs U, Ray KK et al. Bempedoic acid plus ezetimibe fixeddose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol 2020; 27(6): 593–603. Dostupné z DOI: <http://dx.doi. org/10.1177/2047487319864671>.
Ballantyne CM, Bays H, Catapano AL et al. Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther 2021; 35(4): 853–864. Dostupné z DOI: <http://dx.doi.org/10.1007/s10557–021–07147–5>. Erratum in:Cardiovasc Drugs Ther 2021; 35(4): 865. Dostupné z DOI: <http://dx.doi. org/10.1007/s10557–021–07188w>.
Nicholls S, Lincoff AM, Bays HE et al. Rationale and design of the CLEARoutcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J 2021; 235 : 104–112. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2020.10.060>.
Nissen SE, Lincoff AM, Brennan D et al. [CLEAR Outcomes Investigators]. Bempedoic Acid and Cardiovascular Outcomes in StatinIntolerant Patients. N Engl J Med 2023; 13 : 388(15): 1353–1364. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2215024>.
Fábryová Ľ. Manažment pacienta so statínovou intoleranciou v ambulancii všeobecného lekára. Všeobec Lek 2023; 2(2): 73–78.
Nissen SE, Menon V, Nicholls SJ et al. Bempedoic Acid for Primary Prevention of Cardiovascular Events in StatinIntolerant Patients. JAMA 2023; 330(2): 131–140. Dostupné z DOI: <http://dx.doi.org/10.1001/ jama.2023.9696>.
Nicholls SJ, Nelson AJ, Lincoff AM et al. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial. JAMA Cardiol 2024; 9(3): 245–253. Dostupné z DOI: <http://dx.doi.org/10.1001/jamacardio.2023.5155>. Erratum in: JAMA Cardiol 2024; 9(7): 674. Dostupné z DOI: <http://dx.doi. org/10.1001/jamacardio.2024.1279>.
Ray KK, Nicholls SJ, Li N et al. [CLEAR OUTCOMES Committees and Investigators]. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol 2024; 12(1): 19–28. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(23)00316–9>.
Laffin LJ, Brennan D, Mason D et al. Background Ezetimibe Use Among Participants in the CLEAR Outcomes Trial. Poster ID: 316 presented at the American Society for Preventive Cardiology (ASPC) Congress –⁠ 21st23rd July 2023.
Ridker PM, Lei L, Ray KK et al. Effects of bempedoic acid on CRP, IL6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial. J Clin Lipidol 2023; 17(2): 297 –⁠ 302. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacl.2023.02.002>.
Ridker PM, Lei L, Louie MJ et al. [CLEAR Outcomes Investigators]. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary HighRisk Patients With Statin Intolerance. Circulation 2024; 149(1): 28–35. Dostupné z DOI: <http://dx.doi.org/10.1161/ CIRCULATIONAHA.123.066213>.
Fábryová Ľ. Novinky z predšpecifikovaných podskupinových analýz štúdie CLEAROutcomes. AtheroRev 2024; 9(1): 35–40.
Azari S, Pourasghari H, Rezaei MA et al. Fair pricing, fair access; a systematic review of costeffectiveness of new hyperlipidemia injectable medication in developing countries. Cost Eff Resour Alloc 2025; 23(1): 68. Dostupné z DOI: <http://dx.doi.org/10.1186/s12962–025–00671–3>.
Morton JI, Liew D, Watts GF et al. Rethinking cardiovascular prevention: costeffective cholesterol lowering for statinintolerant patients in Australia and the UK. Eur J Prev Cardiol 2025; 32(13): 1259–1270. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjpc/zwaf114>.
Averna M, GouniBerthold I, Jukema WJ. et al. Evaluating dyslipidaemia treatment with bempedoic acid and ezetimibe over 8 weeks in the Italian cohort of the MILOS observational study. Eur Heart J Suppl 2025; 27(Suppl_5): suaf076.356. Dostupné z DOI: <http://dx.doi.org/10.1093/ eurheartjsupp/suaf076.356>.
GouniBerthold I, Koskinas, K, Averna M et al. Effectiveness and safety of bempedoic acid in routine clinical practice: 1year followup snapshot of the MILOS German cohort. Eur Heart J 2023; 44(Suppl_2): ehad655.2810. Dostupné z DOI: <http://doi 10.1093/eurheartj/ehad 655.2810>.